University of Minnesota Cancer Center Achieves ‘Comprehensive’ Status

Publication
Article
OncologyONCOLOGY Vol 12 No 11
Volume 12
Issue 11

The University of Minnesota Cancer Center has been designated a "comprehensive cancer center" by the National Cancer Institute. To quality for the title "comprehensive," a center must conduct basic and clinical research, as well as prevention, control, and population studies; exhibit a strong body of interactive research bridging these key areas; and have outreach, education, and information programs in place. Only 35 of the 58 NCI-designated cancer centers meet the requirements for the "comprehensive" designation.

The University of Minnesota Cancer Center has been designated a "comprehensive cancer center" by the National Cancer Institute. To quality for the title "comprehensive," a center must conduct basic and clinical research, as well as prevention, control, and population studies; exhibit a strong body of interactive research bridging these key areas; and have outreach, education, and information programs in place. Only 35 of the 58 NCI-designated cancer centers meet the requirements for the "comprehensive" designation.

"We’re extremely pleased that the National Cancer Institute and our national peers have recognized the breadth of our cancer research program as well as our efforts to serve the community," said John H. Kersey, MD, director of the University of Minnesota Cancer Center. The University of Minnesota Cancer Center is the only NCI-designated comprehensive cancer center in the state of Minnesota

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content